OIP	1 5:00
E 257 1	\$ 2003 July
The second second	180b2

Similar Simi	28 64 28 28 10 27	:	FILING DATE 12/27/72 6/7/74 10/1/75 2/2/76 5/24/83
PTO-1449	ASS 28 64 28 10 27 28	SUBCLAS S 260 49 260 260 697	DATE 12/27/72 6/7/74 10/1/75 2/2/76
FILING DATE: 07/28/03 US PATENT DOCUMENTS	ASS 28 64 28 10 27 28	SUBCLAS S 260 49 260 260 697	DATE 12/27/72 6/7/74 10/1/75 2/2/76
US PATENT DOCUMENTS EXAMINER'S INITIALS PATENT NO. INITIALS DATE INITIALS NAME INITIALS CI EA 3,797,492 3/19/74 Place 12 1 3,923,939 12/2/75 Baker et al. 26 2 3,987,790 10/26/76 Eckenhoff et al. 12 4,008,719 2/22/77 Theeuwes et al. 12 4,4443,340 4/17/84 May et al. 22 4,586,559 2/4/86 Nuwayser et al. 42 4,623,588 11/18/86 Nuwayser et al. 43 4,668,506 5/26/87 Bawa 44 4,708,861 11/24/87 Popescu et al. 45 4,711,782 12/8/87 Okada et al. 45 4,713,244 12/15/87 Bawa et al. 45 4,853,218 8/1/89 Yim et al. 45 4,866,050 9/12/89 Eckenhoff et al. 45 4,931,279 6/5/90 Bawa et al. 46 4,931,279 6	ASS 28 64 28 10 27 28	SUBCLAS S 260 49 260 260 697	DATE 12/27/72 6/7/74 10/1/75 2/2/76
EXAMINER'S PATENT NO. DATE NAME CI	28 64 28 28 10 27	260 49 260 260 697	DATE 12/27/72 6/7/74 10/1/75 2/2/76
Sample	28 64 28 28 10 27	260 49 260 260 697	DATE 12/27/72 6/7/74 10/1/75 2/2/76
3,923,939 12/2/75 Baker et al. 26 3,987,790 10/26/76 Eckenhoff et al. 12 4,008,719 2/22/77 Theeuwes et al. 12 4,443,340 4/17/84 May et al. 26 4,586,559 2/4/86 Nuwayser et al. 42 4,623,588 11/18/86 Nuwayser et al. 42 4,668,506 5/26/87 Bawa 42 4,708,861 11/24/87 Popescu et al. 42 4,711,782 12/8/87 Okada et al. 42 4,713,244 12/15/87 Bawa et al. 42 4,853,218 8/1/89 Yim et al. 42 4,865,845 9/12/89 Eckenhoff et al. 43 4,866,050 9/12/89 Ben-Amoz 55 4,931,279 6/5/90 Bawa et al. 43 4,938,763 7/3/90 Dunn et al. 66	64 28 28 10 27	49 260 260 697	6/7/74 10/1/75 2/2/76
3,987,790 10/26/76 Eckenhoff et al. 12 4,008,719 2/22/77 Theeuwes et al. 12 4,443,340 4/17/84 May et al. 22 4,586,559 2/4/86 Nuwayser et al. 42 4,623,588 11/18/86 Nuwayser et al. 42 4,668,506 5/26/87 Bawa 42 4,708,861 11/24/87 Popescu et al. 42 4,711,782 12/8/87 Okada et al. 42 4,713,244 12/15/87 Bawa et al. 42 4,853,218 8/1/89 Yim et al. 42 4,865,845 9/12/89 Eckenhoff et al. 42 4,866,050 9/12/89 Ben-Amoz 5 4,931,279 6/5/90 Bawa et al. 42 4,938,763 7/3/90 Dunn et al. 66	28 28 10 27	260 260 697	10/1/75 2/2/76
4,008,719 2/22/77 Theeuwes et al. 12 4,443,340 4/17/84 May et al. 22 4,586,559 2/4/86 Nuwayser et al. 42 4,623,588 11/18/86 Nuwayser et al. 42 4,668,506 5/26/87 Bawa 42 4,708,861 11/24/87 Popescu et al. 42 4,711,782 12/8/87 Okada et al. 43 4,713,244 12/15/87 Bawa et al. 43 4,853,218 8/1/89 Yim et al. 43 4,865,845 9/12/89 Eckenhoff et al. 43 4,931,279 6/5/90 Bawa et al. 43 4,938,763 7/3/90 Dunn et al. 66	28 10 27 28	260 697	2/2/76
4,443,340 4/17/84 May et al. 2.4 4,586,559 2/4/86 Nuwayser et al. 4.5 4,623,588 11/18/86 Nuwayser et al. 4.5 4,668,506 5/26/87 Bawa 4.5 4,708,861 11/24/87 Popescu et al. 4.5 4,711,782 12/8/87 Okada et al. 4.5 4,713,244 12/15/87 Bawa et al. 4.5 4,853,218 8/1/89 Yim et al. 4.5 4,865,845 9/12/89 Eckenhoff et al. 4.5 4,931,279 6/5/90 Bawa et al. 4.5 4,938,763 7/3/90 Dunn et al. 6	10 27 28	697	
4,586,559 2/4/86 Nuwayser et al. 42 4,623,588 11/18/86 Nuwayser et al. 42 4,668,506 5/26/87 Bawa 42 4,708,861 11/24/87 Popescu et al. 42 4,711,782 12/8/87 Okada et al. 43 4,713,244 12/15/87 Bawa et al. 43 4,853,218 8/1/89 Yim et al. 43 4,865,845 9/12/89 Eckenhoff et al. 43 4,931,279 6/5/90 Bawa et al. 43 4,938,763 7/3/90 Dunn et al. 66	27		5/24/83
4,623,588 11/18/86 Nuwayser et al. 42 4,668,506 5/26/87 Bawa 42 4,708,861 11/24/87 Popescu et al. 43 4,711,782 12/8/87 Okada et al. 43 4,713,244 12/15/87 Bawa et al. 43 4,853,218 8/1/89 Yim et al. 43 4,865,845 9/12/89 Eckenhoff et al. 43 4,866,050 9/12/89 Ben-Amoz 55 4,931,279 6/5/90 Bawa et al. 43 4,938,763 7/3/90 Dunn et al. 66	28	3	J. = 7/00
4,668,506 5/26/87 Bawa 42 4,708,861 11/24/87 Popescu et al. 42 4,711,782 12/8/87 Okada et al. 43 4,713,244 12/15/87 Bawa et al. 44 4,853,218 8/1/89 Yim et al. 43 4,865,845 9/12/89 Eckenhoff et al. 44 4,866,050 9/12/89 Ben-Amoz 55 4,931,279 6/5/90 Bawa et al. 44 4,938,763 7/3/90 Dunn et al. 66		_	2/6/84
4,708,861 11/24/87 Popescu et al. 42 4,711,782 12/8/87 Okada et al. 43 4,713,244 12/15/87 Bawa et al. 44 4,853,218 8/1/89 Yim et al. 45 4,865,845 9/12/89 Eckenhoff et al. 45 4,866,050 9/12/89 Ben-Amoz 55 4,931,279 6/5/90 Bawa et al. 45 4,938,763 7/3/90 Dunn et al. 66		402.24	12/2/85
4,711,782 12/8/87 Okada et al. 42 4,713,244 12/15/87 Bawa et al. 43 4,853,218 8/1/89 Yim et al. 43 4,865,845 9/12/89 Eckenhoff et al. 43 4,866,050 9/12/89 Ben-Amoz 53 4,931,279 6/5/90 Bawa et al. 43 4,938,763 7/3/90 Dunn et al. 66	24	429	8/16/85
4,711,782 12/8/87 Okada et al. 45 4,713,244 12/15/87 Bawa et al. 45 4,853,218 8/1/89 Yim et al. 45 4,865,845 9/12/89 Eckenhoff et al. 45 4,866,050 9/12/89 Ben-Amoz 55 4,931,279 6/5/90 Bawa et al. 45 4,938,763 7/3/90 Dunn et al. 66	24	1.1	1/31/85
4,713,244 12/15/87 Bawa et al. 45 4,853,218 8/1/89 Yim et al. 45 4,865,845 9/12/89 Eckenhoff et al. 45 4,866,050 9/12/89 Ben-Amoz 55 4,931,279 6/5/90 Bawa et al. 45 4,938,763 7/3/90 Dunn et al. 66	24	455	12/11/86
4,853,218 8/1/89 Yim et al. 4/3 4,865,845 9/12/89 Eckenhoff et al. 4/3 4,866,050 9/12/89 Ben-Amoz 5/3 4,931,279 6/5/90 Bawa et al. 4/3 4,938,763 7/3/90 Dunn et al. 6/3	24	429	8/16/85
4,865,845 9/12/89 Eckenhoff et al. 4/2 4,866,050 9/12/89 Ben-Amoz 5/2 4,931,279 6/5/90 Bawa et al. 4/2 4,938,763 7/3/90 Dunn et al. 6/2	24	85.7	2/24/87
4,866,050 9/12/89 Ben-Amoz 5 4,931,279 6/5/90 Bawa et al. 4 4,938,763 7/3/90 Dunn et al. 6	24	424	9/12/89
4,931,279 6/5/90 Bawa et al. 4: 4,938,763 7/3/90 Dunn et al. 6	14	179	4/27/88
4,938,763 7/3/90 Dunn et al. 6	24	427	7/21/88
	04	891.1	10/03/88
4,985,404 1/15/91 Mitchell et al. 5	14	6	6/29/88
	24	497	5/1/89
	24	438	4/23/90
	24	438	4/23/90
	24	423	1/24/90
	14	668	8/7/90
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	24	481	12/2/88
	24	422	9/14/89
	24	422	6/12/91
	04	892.1	10/29/90
	04	307	5/6/92
()	04	892.1	2/18/92
, , , , , , , , , , , , , , , , , , , ,		473	9/2/92
EXAMINER: /Ernst Arnold/ DATE CONSIDERE	24	/20/2007	<u> </u>

ENT & INFO	RMATION DISCLO CITATION Sheet 1 of 2	SURE	ATTORNEY'S I ARC 3119 R			CATION NO.: 2 8,984	
	PTO-1449		APPLICANT: Chen et al. FILING DATE:		GROU		
			07/28/03	JENTO.	Una	ssigned	
			ENT DOCUM		40.4	170	9/2/92
EA	5,234,693	8/10/93	Magruder e	t ai.	424	473	10/13/92
	5,242,910	9/7/93	Damanj		514	152	
	5,252,318	10/12/93	Joshi et al.		424	78.04	6/15/90
	5,278,201	1/11/94	Dunn et al.		523	133	4/24/90
	5,279,608	1/18/94	Cheikh		604	892.1	12/4/91
	5,308,348	5/3/94	Balaban et		644	891.1	5/5/93
	5,310,865	5/10/94	Katashi En	omoto et al.	528	361	12/18/92
	5,324,519	6/28/94	Dunn et al.		424	426	10/28/91
	5,300,295	8/5/94	Viegas et a	l.	424	427	9/13/91
	5,336,057	8/9/94	Toshio Fuk	uda et al.	417	395	7/20/93
	5,330,452	7/19,94	Zook		604	307	6/1/93
	5,340,614	8/23/94	Perman et a	al.	427	2.24	2/11/93
	5,342,627	8/30/627	Chopra et a	ıl.	424	473	11/12/92
	5,415,866	5/16/95	Zook		424	448	7/12/93
	5,540,912	7/30/96	Roorda et a	nl.	424	422	3/30/93
	5,441,732	8/15,95	Hoeg et al.		424	78.04	3/18/92
	5,447,725	9/5/95	Damani et a	al.	424	435	6/11/93
	5,456,679	10/10/95	Balaban et	al.	604	892.1	12/7/94
	5,487,897	1/30/96	Polson et a	1.	424	426	9/28/93
	5,540,912	7/30/96	Roorda et a		424	422	7/30/96
	5,543,156	8/6/96	Roorda et a	al.	424	484	1/21/94
	5.556,905	9/17/96	Frappier et	al.	524	311	3/30/94
	5,571,525	11/5/96	Roorda et a		424	426	3/30/94
	5,787,175	12/24/96	Viegas et a	î.	424	427	12/28/93
	5,599,534	2/4/97	Himmelste		424	78.04	8/9/94
	5,599,552	2/4/97	Dunn et al.		424	423	5/26/94
	5,610,184	3/11/97	Shahinian,		514	540	3/3/95
	5,618,563	4/8/97	Berde et al		424	501	9/10/93
	5,620,700	4/15/97	Berggen et		424	435	5/9/95
	5,651,986	7/29/97	Brem et al.		424	484	6/14/96
EA	5,654,010	8/5/97	Johnson et		424	502	7/7/95
EXAMINER:		Arnold/			L	2/20/2007	

COUNTRY	RMATION DISCLO CITATION	SURE	ATTORNEY'S DOCKET NO.: ARC 3119 R1		ICATION NO.: 28,984	
	CITATION		ARC 3119 KT	10/0	20,304	
	Sheet 1 of 3				<u>.</u>	
	PTO-1449		APPLICANT: Chen et al.			
			FILING DATE:	GRO		
			07/28/03	Una	ssigned	
		US PAT	ENT DOCUMENTS			1
EA	5,656,297	8/12/97	Bernstein et al.	424	484	5/3/94
A	5,660,817	8/26/97	Masterman et al.	424	49	11/9/94
	5,674,292	10/7/97	Tucker et al.	623	16	7/7/95
	5,618,563	4/8/97	Berde et al.	424	501	9/10/93
	5,681,873	10/28,97	Norton et al.	523	115	10/14/93
	5,700,485	12/23/97	Berde et al.	424	501	5/1/95
	5,707,664	1/13/98	Illum	424	434	12/20/94
	5,708,011	1/13/98	Bardsley et al.	514	330	10/13/94
	5,733,950	3/31/98	Dunn et al.	523	113	9/25/95
	5,744,153	4/28/98	Yewey et al.	424	426	6/9/97
	5,747,058	5/5/98	Tipton et al.	424	337	6/7/95
	5,747,060	5/5/98	Sackler et al.	424	426	3/26/96
	5,759,563	6/2/98	Yewey et al.	424	426	6/7/95
	5,760,077	6/2/98	Shahinian Jr.	514	540	3/11/97
	5,766,637	6/16/98	Shine et al.	424	497	10/8/96
	5,780,044	7/14/98	Yewey et al.	424	426	12/5/96
	5,783,205	7/21/98	Berggren et al.	424	426	4/10/97
	5,804,212	9/8/98	Illum	424	434	6/17/97
	5,849,763	12/15/98	Bardsley et al.	514	445	10/27/9
	5,910, 502	6/8/99	Gennery	514	330	3/3/98
	5,922,340	7/13/99	Berde et al.	424	426	9/16/96
	5,942,241	8/24/99	Chasin et al.	424	426	6/7/96
	5,955,479	9/21/99	Bardsley et al.	514	330	10/13/94
	5,958,443	9/28/99	Viegas et al.	424	427	12/23/9
	5,972,326	10/26/99	Galin et al.	424	78.04	3/18/97
	5,972,366	10/26/99	Haynes et al.	424	422	9/17/96
	5,990,194	11/23/99	Dunn et al.	523	113	11/7/97
	5,919,835	7/6/99	Domb et al.	523	113	12/23/9
	6,004,295	12/21/99	Langer et al.	604	164	6/26/98
	6,046,187	4/4/00	Berde et al.	514	180	9/16/96
EA	6,050,986	4/18/00	Hektner	604	508	12/1/97
XAMINER:	/Ernst Arı		DATE CONSI		02/20/2	

THEO	RMATION DISCLOSU CITATION Sheet 1 of 4	IRE	ATTORNEYS ARC 3119	DOCKET NO.: R1		LICATION NO. 328,984	•
	PTO-1449		APPLICANT:				
	•		Chen et al		GRO	NID:	· · · · · · · · · · · · · · · · · · ·
			07/28/03	••		assigned	
		US PATE	NT DOCL	MENTS			
EA	6,086,909	7/11/00	Harrison	et al.	424	430	2/12/99
1	6,103,266	8/15/00	Tapolski	et al.	424	484	4/22/98
	6,106,301	8/22/00	Merril		434	262	9/4/97
	6,117,425	9/12/00	McPhee	et al.	424	94.64	7/7/95
	6,120,789	9/19/00	Dunn		424	426	3/30/99
	6,120,804	9/19/00	Drizen et	al.	424	488	4/8/99
	6,129,933	10/10/00	Oshlack	et al.	424	495	7/24/97
	6,130,200	10/10/00	Brodbec	k et al.	514	2	12/18/97
	6,136,334	10/24/00	Viegas e	t al.	424	427	6/11/97
	6,143,314	11/7/00	Chandea	shekar et al.	424	426	10/28/98
	6,193,991	2/27/01	Shukla		424	426	10/28/98
	6,193,994	2/27/01	Lee at al.		424	444	5/22/97
	6,197,327	3/6/01	Harrison	et al.	424	430	5/15/98
	6,214,387	4/10/01	Berde et	al.	424	501	9/17/97
	6,217,911	4/17/01	Vaung et	al.	424	501	7/5/96
	6,238,702	5/29/01	Berde et	al.	424	489	7/12/99
	6,248,345	6/19/01	Goldenh	eim et al.	424	426	7/2/98
'	6,255,502	7/3/01	Penkler e	et al.	552	549	7/11/97
· ·	6,261,547	7/17/01	Bawa et	al.	424	78.04	11/23/99
	6,309,375	10/30/01	Glines et	al.	604	187	5/18/99
	6,322,548	11/27/01	Payne et	al.	604	500	3/31/98
	6,352,667	3/5/02	English		264	328.17	8/24/99
	6,355,273	3/12/02	Carli et a	l.	424	489	8/4/00
	6,372,245	4/16/02	Bowman	et al.	424	427	4/22/94
	6,375,659	4/24/02	Erbe et a	l.	606	94	2/20/01
	6,395,293	5/28/02	Polson e	t al.	424	426	3/8/00
	6,403,057	6/11/02	Schneide	er et al.	424	9.52	6/23/00
	6,417,201	7/9/02	Bardsley	et al.	514	330	7/12/00
	6,426,339	7/30/02	Berde et	al.	514	180	4/3/00
	6,432,415	8/13/02	Osborne	et al.	424	400	12/17/99
(6,423,818	7/23/02	Matsuda	et al.	528	354	7/26/00
	6,451,346	9/17/02	Shah		424	486	12/23/98
EA	6,543,081	3/18/03	Goldenh	eim et al.	424	426	4/2/01
XAMINER:	/Ernst Arno	old/		DATE CONSIDE	RED:	02/20/2	007

MA FO	RMATION DISCLOSUR DISCUSSION Sheet 1 of 5	E	ATTORNEY'S DOCKET NO.: ARC 3119 R1		100 NO 10	:
	PTO-1449	• •	APPLICANT:			
		1	Chen et al.	GRO	VIID.	
			FILING DATE: 07/28/03		assigned	
		US PATI	ENT DOCUMENTS			
EA	US 2001/0004644 A1	6/21/01	Levin	514	646	12/15/00
1	US 2001/0046518 A1	11/29/01	Sawhney	424	486	8/14/98
	US 2001/0055607 A1	12/27/01	Levin	424	435	7/17/98
	US 2002/0015712 A1	2/7/02	Mchride et al.	424	400	5/23/00
	US 2002/0001608 A1	1/3/02	Polson et al.	424	426	3/8/00
	US 2002/0010150 A1	1/24/02	Cortese et al.	514	54	4/26/01
	US 2002/0016338 A1	2/7/02	Mather et al.	514	317	10/1/01
	US 2002/0028243 A1	3/7/02	Masters	424	484	2/28/01
	US 2002/0028181 A1	3/7/02	Miller et al.	424	43	4/26/01
	US 2002/0037104 A1	11/1/01	Zhang et al.	604	502	2/28/01
	US 2002/0037358 A1	3/28/02	Barry et al.	427	2.1	10/18/01
	US 2002/0039594 A1	4/4/02	Unger	424	426	5/11/98
	US 2002/0004063 A1	1/10/02	Zhang	424	443	9/28/99
	US 2002/0045668 A1	4/18/02	Dang et al.	514	649	7/17/01
	US 2002/0054915 A1	5/9/02	Goldenheim et al.	424	497	4/2/01
	US 2002/0061326 A1	5/23/02	Wei-Ping Li et al.	424	424	1/2/01
EA	US 2002/0086971 A1	7/14/02	Pham	528	354	2/1/02
-	F	OREIGN F	PATENT DOCUMENTS			
EA	WO 93/24150		PCT			
EA	WO 95/13799		PCT			
Ī	WO 98/27962		PCT			
	WO 98/27963		PCT			
	WO 99/47073		PCT			
	WO 00/74650 A2		PCT			
	WO 02/058670 A1		PCT			
	WO 02/067991 A1		PCT			
1	WO 03/041685 A1		PCT .			
1	WO 03/041684 A2		PCT			
EA	WO 03/041757 A2		PCT			
HG	OTHER DOCUMEN	NTS (inclu	ding Author, Title, Date, Pe	rtinent Pa	ges etc.)	
	Cleland, J. L. "Injectable Symp. Control. Rel. Bio		Local and Systemic Delivers, Vol. 28, 2001.	ery of Prote	eins," <u>Proce</u>	ed. Int'l.
XAMINER:	/Ernst Arn	old/	DATE CONSI	DERED: 02	2/20/2007	

By The second	SE					
INFOR	MATION DISCLOSURE CITATION Sheet 1 of 6 PTO-1449	ATTORNEY'S DOCKET NO. ARC 3119 R1 APPLICANT: Chen et al.	: APPLICATION NO.: 10/628,984			
		FILING DATE: 07/28/03	GROUP: Unassigned			
	OTHER DOCUMENTS (include					
EA	Blanco, M. D. et al. "Bupivacair a poly(lactide-coglycolide) film Blomaterials, Vol. 20, pp.1919-1	: in vivo blocompatibility an	by alumin microspheres included in drug release studies,"			
EA	Duenas, E. et al. "Sustained De Int'l. Symp. Control. Rel. Bloac		vel Injectable Liquid, Plad" <u>Proceed.</u>			
EA	Guevello, P. Le at al. "High-performance liquid chromatographic determination of bupivacain in plasma samples for biopharmaveutical studies and application to seven other local anaesthetics," <u>Journal of Chromatography</u> , Vol. 622, pp. 284-290, (1993).					
EA	Garry, M. G. et al. "Evaluation of antinociception and inflammate		ible bupivacaine polymer system on vol. 82, pp. 49-55, 1999.			
EA	system for controlled release of (1995).	f proteins," <u>Journal of Cont</u>	degradable poly-lactide-co-glycolide trolled Release, Vol. 33, pp. 189-195			
EA	Okumu, F. W. et al. "Sustained Plad," Proceed. Int'l. Symp. Co		ne from a Novel Injectable Liquid, bl. 28, 2001.			
EA	Okumu, F. W. et al. "Evaluation Growth Hormone – Formulation Control. Rel. Bioact. Mater., Vo	n Design and <i>In Vivo</i> Asses				
EA	Philip, B. K. et al. "The Econom Journal of Clinical Anesthesia,		estoperative Pain Management,"			
			•			
EXAMINER:			02/20/2007			
	/Ernst Arnold/	DATE CONS	SIDERED: 02/20/2007			

PTO/SB/08A (10-01) Approved for use through 10/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

> Complete if Known 10/628,984

July 28, 2003

Chen et al.

Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Filing Date First Named Inventor

Application Number

Group Art Unit 1615 Examiner Name Unknown

(use as many sheets as necessary) ARC 3119R1 (3139-6226.1US) Sheet of Attorney Docket Number

	Т		U.S. PATENT D	Name of Patentee or Applicant of	
Examiner Initials •	Cite No. ¹	Number - Kind Code ² (If known)	Publication Date MM-DD-YYYY	Cited Document	Pages, Cohmms, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-	l		
		US-			
	Γ	US-			
		US-	, , , ,		
		US-			
	l	US-			
		US-			
		US-			
	T	US-			
		US-			

	FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,		
Initials*	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (If known)	Publication Date MM-DD-YYYY	Applicant of Cited Document		Where Relevant Passages or Relevant Figures Appear	T ⁶
EA		WO 02/45689 A1	06/13/2002	Seo et al.			
-							
	I						

_				
	Examiner Signature	/Ernst Arnold/	Date Considered	02/20/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

4

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
EA		JAIN, Rajeev A., "The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices," Biomaterials 21: 2475-2490 (2002).					
EA		RIVIVARAPU et al., "Polymer and microsphere blending to alter the release of a peptide from PLGA microspheres," European Journal of Pharmaceutics and Biopharmaceutics 50: 263-270 (2002).					
EA		International Search Report, dated February 9, 2004 (4 pages).					
		·					
		·					

Examiner	/Ernst Arnold/	Date	02/20/2007
Signature		Considered	02/20/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

_...

¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.